Chondroguard (sodium chondroitin sulfate) 100 mg/ml x 10 ampoules solution
- $54.40
The instruction for medical use
of Hondrogard Torgovoye medicine a name
Hondrogard
Mezhdunarodnoye the unlicensed name
Is not present
the Dosage form
Solution for intramuscular introduction of 100 mg/ml
Structure
1 ampoule contains
active agent: chondroitin sodium sulfate - 100 mg,
excipients: benzyl alcohol, sodium metabisulphite,
sodium hydroxide, water for injections.
The description
Transparent colourless or with slightly yellowish shade solution with a smell of benzyl alcohol
Pharmacotherapeutic group
Non-steroidal anti-inflammatory drugs others.
ATH M01AX25 code
Pharmacological action
Pharmacokinetics
After intramuscular administration of chondroitin sulfate is quickly distributed. In 30 min. after an injection it is found in blood in considerable concentration. The maximum concentration (Cmax) of chondroitin of sulfate in plasma is reached in 1 h, then gradually decreases within 2 days.
Chondroitin sulfate collects, mainly, in cartilaginous tissue of joints. The synovial membrane is not an obstacle for penetration of drug into a joint cavity. In experiments it is shown that in 15 min. after an intramuscular injection of chondroitin sulfate is found in synovial fluid, then gets into a joint cartilage where its Cmax is reached in 48 h. It is brought out of an organism within 24 hours. It Eliminirutsya mainly by kidneys.
A pharmacodynamics
Chondroitin sulfate - the high-molecular mucopolysaccharide influencing exchange processes in a hyaline cartilage. Reduces degenerative changes in cartilaginous tissue of joints, accelerates processes of its restoration, stimulates synthesis of proteoglycans, has hondroprotektivny, anti-inflammatory, analgeziruyushchy effect.
At drug treatment the morbidity decreases and the mobility of the affected joints improves. At treatment of degenerative changes
of joints with development of a secondary synovitis, the positive effect can
be observed in 2-3 weeks after the beginning of administration of drug the joint pain decreases, clinical manifestations of a reactive
synovitis disappear, the volume of movements in the affected joints increases.
The therapeutic effect remains a long time after the termination
of a course of treatment.
Indications
Degenerative dystrophic diseases of joints and backbone:
- an osteoarthrosis with primary damage of large joints
- intervertebral osteochondrosis
the Route of administration and doses
appoint Drug intramusculary on 100 mg every other day. At good tolerance the dose is increased to 200 mg, since the fourth injection.
A course of treatment - 25-30 injections. If necessary in 6 months carrying out a repeated course of treatment is possible.
Side effect
Allergic reactions (skin itching, an erythema, a small tortoiseshell, dermatitis),
hemorrhages in the place of an injection
of the Contraindication
- hypersensitivity to drug or to its components
- bleedings and tendency to bleeding
- thrombophlebitises
- pregnancy and the period of a lactation
- children's age up to 18 years
Medicinal interactions
At the combined use with non-steroidal anti-inflammatory drugs Hondrogard allows to lower a dose of non-steroidal anti-inflammatory drugs. Drug strengthens effect of indirect anticoagulants, antiagregant, fibrinolitik that demands more frequent control of indicators of fibrillation at combined use.
Special instructions
achievement of stable clinical effect requires not less than 25 injections of Hondrogard. For prevention of aggravations repeated courses of treatment are shown.
Use in pediatrics
the Data on efficiency and safety of use of chondroitin of sulfate for children are absent now.
Features of influence of medicine on ability to run
the vehicle or potentially dangerous mechanisms
the Overdose does not influence
Now about cases of overdose of chondroitin of sulfate
it was not reported.
A form of release and packing
Solution for intramuscular introduction of 100 mg/ml.
On 1 ml in ampoules of colourless neutral glass with a color ring
of a break or with a color point and a notch and/or with additional
color identification rings or other coding.
On 5 ampoules in blister strip packaging from a film of polyvinylchloride
and aluminum foil, or a film polymeric, or without foil and a film.
On the 2nd blister strip packagings together with the instruction for medical
use in the state and Russian languages in a pack from cardboard.
To Store storage conditions in the place protected from light at a temperature not over 25C.
To store out of children's reach!
2 years
not to use a period of storage after an expiration date.
of Hondrogard Torgovoye medicine a name
Hondrogard
Mezhdunarodnoye the unlicensed name
Is not present
the Dosage form
Solution for intramuscular introduction of 100 mg/ml
Structure
1 ampoule contains
active agent: chondroitin sodium sulfate - 100 mg,
excipients: benzyl alcohol, sodium metabisulphite,
sodium hydroxide, water for injections.
The description
Transparent colourless or with slightly yellowish shade solution with a smell of benzyl alcohol
Pharmacotherapeutic group
Non-steroidal anti-inflammatory drugs others.
ATH M01AX25 code
Pharmacological action
Pharmacokinetics
After intramuscular administration of chondroitin sulfate is quickly distributed. In 30 min. after an injection it is found in blood in considerable concentration. The maximum concentration (Cmax) of chondroitin of sulfate in plasma is reached in 1 h, then gradually decreases within 2 days.
Chondroitin sulfate collects, mainly, in cartilaginous tissue of joints. The synovial membrane is not an obstacle for penetration of drug into a joint cavity. In experiments it is shown that in 15 min. after an intramuscular injection of chondroitin sulfate is found in synovial fluid, then gets into a joint cartilage where its Cmax is reached in 48 h. It is brought out of an organism within 24 hours. It Eliminirutsya mainly by kidneys.
A pharmacodynamics
Chondroitin sulfate - the high-molecular mucopolysaccharide influencing exchange processes in a hyaline cartilage. Reduces degenerative changes in cartilaginous tissue of joints, accelerates processes of its restoration, stimulates synthesis of proteoglycans, has hondroprotektivny, anti-inflammatory, analgeziruyushchy effect.
At drug treatment the morbidity decreases and the mobility of the affected joints improves. At treatment of degenerative changes
of joints with development of a secondary synovitis, the positive effect can
be observed in 2-3 weeks after the beginning of administration of drug the joint pain decreases, clinical manifestations of a reactive
synovitis disappear, the volume of movements in the affected joints increases.
The therapeutic effect remains a long time after the termination
of a course of treatment.
Indications
Degenerative dystrophic diseases of joints and backbone:
- an osteoarthrosis with primary damage of large joints
- intervertebral osteochondrosis
the Route of administration and doses
appoint Drug intramusculary on 100 mg every other day. At good tolerance the dose is increased to 200 mg, since the fourth injection.
A course of treatment - 25-30 injections. If necessary in 6 months carrying out a repeated course of treatment is possible.
Side effect
Allergic reactions (skin itching, an erythema, a small tortoiseshell, dermatitis),
hemorrhages in the place of an injection
of the Contraindication
- hypersensitivity to drug or to its components
- bleedings and tendency to bleeding
- thrombophlebitises
- pregnancy and the period of a lactation
- children's age up to 18 years
Medicinal interactions
At the combined use with non-steroidal anti-inflammatory drugs Hondrogard allows to lower a dose of non-steroidal anti-inflammatory drugs. Drug strengthens effect of indirect anticoagulants, antiagregant, fibrinolitik that demands more frequent control of indicators of fibrillation at combined use.
Special instructions
achievement of stable clinical effect requires not less than 25 injections of Hondrogard. For prevention of aggravations repeated courses of treatment are shown.
Use in pediatrics
the Data on efficiency and safety of use of chondroitin of sulfate for children are absent now.
Features of influence of medicine on ability to run
the vehicle or potentially dangerous mechanisms
the Overdose does not influence
Now about cases of overdose of chondroitin of sulfate
it was not reported.
A form of release and packing
Solution for intramuscular introduction of 100 mg/ml.
On 1 ml in ampoules of colourless neutral glass with a color ring
of a break or with a color point and a notch and/or with additional
color identification rings or other coding.
On 5 ampoules in blister strip packaging from a film of polyvinylchloride
and aluminum foil, or a film polymeric, or without foil and a film.
On the 2nd blister strip packagings together with the instruction for medical
use in the state and Russian languages in a pack from cardboard.
To Store storage conditions in the place protected from light at a temperature not over 25C.
To store out of children's reach!
2 years
not to use a period of storage after an expiration date.
Related Products
